Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy

Grywalska, Ewelina; Sosnowska-Pasiarska, Barbara; Smok-Kalwat, Jolanta; Pasiarski, Marcin; Niedźwiedzka-Rystwej, Paulina; Roliński, Jacek

doi:10.3390/cells9040983

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessReview

Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy

Ewelina Grywalska

^1,2,*

Barbara Sosnowska-Pasiarska

³,

Jolanta Smok-Kalwat

⁴,

Marcin Pasiarski

^5,6,

Paulina Niedźwiedzka-Rystwej

⁷

and

Jacek Roliński

^1,2

Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland

St. John’s Cancer Centre, 20-090 Lublin, Poland

Department of Oncocardiology, Holy Cross Cancer Centre, 25-734 Kielce, Poland

⁴

Department of Clinical Oncology, Holy Cross Cancer Centre, 25-734 Kielce, Poland

⁵

Department of Immunology, Faculty of Health Sciences, Jan Kochanowski University, 25-317 Kielce, Poland

⁶

Department of Hematology, Holy Cross Cancer Centre, 25-734 Kielce, Poland

⁷

Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland

Author to whom correspondence should be addressed.

Cells 2020, 9(4), 983; https://doi.org/10.3390/cells9040983

Received: 7 March 2020 / Revised: 10 April 2020 / Accepted: 13 April 2020 / Published: 16 April 2020

(This article belongs to the Special Issue Chimeric Antigen Receptor T-Cell Therapy)

View Full-Text Download PDF

Browse Figure

Citation Export

Abstract

Despite the significant progress of modern anticancer therapies, multiple myeloma (MM) is still incurable for the majority of patients. Following almost three decades of development, chimeric antigen receptor (CAR) T-cell therapy now has the opportunity to revolutionize the treatment landscape and meet the unmet clinical need. However, there are still several major hurdles to overcome. Here we discuss the recent advances of CAR T-cell therapy for MM with an emphasis on future directions and possible risks. Currently, CAR T-cell therapy for MM is at the first stage of clinical studies, and most studies have focused on CAR T cells targeting B cell maturation antigen (BCMA), but other antigens such as cluster of differentiation 138 (CD138, syndecan-1) are also being evaluated. Although this therapy is associated with side effects, such as cytokine release syndrome and neurotoxicity, and relapses have been observed, the benefit–risk balance and huge potential drive the ongoing clinical progress. To fulfill the promise of recent clinical trial success and maximize the potential of CAR T, future efforts should focus on the reduction of side effects, novel targeted antigens, combinatorial uses of different types of CAR T, and development of CAR T cells targeting more than one antigen. View Full-Text

Keywords: multiple myeloma; chimeric antigen receptor T (CAR T); BCMA; immunotherapy

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Share and Cite

MDPI and ACS Style

Grywalska, E.; Sosnowska-Pasiarska, B.; Smok-Kalwat, J.; Pasiarski, M.; Niedźwiedzka-Rystwej, P.; Roliński, J. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. Cells 2020, 9, 983. https://doi.org/10.3390/cells9040983

AMA Style

Grywalska E, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, Niedźwiedzka-Rystwej P, Roliński J. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. Cells. 2020; 9(4):983. https://doi.org/10.3390/cells9040983

Chicago/Turabian Style

Grywalska, Ewelina, Barbara Sosnowska-Pasiarska, Jolanta Smok-Kalwat, Marcin Pasiarski, Paulina Niedźwiedzka-Rystwej, and Jacek Roliński. 2020. "Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy" Cells 9, no. 4: 983. https://doi.org/10.3390/cells9040983

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI